MAPT and early-onset autosomal dominant Alzheimer disease: Numerous therapeutic approaches targeting tau, neuroinflammation, and other mechanisms to remedy the causes of Alzheimer’s disease have been evaluated or are currently being evaluated in clinical trials [27], with the majority of attempts to bring efficacious therapies to patients resulting in failure [28].